, Volume 11, Issue 6, pp 575–580 | Cite as

Variation in polyol levels in cerebrospinal fluid and serum in diabetic patients

  • C. Servo
  • E. Pitkänen


Cerebrospinal fluid (CSF) or CSF and plasma levels of sorbitol, 1,5-anhydroglucitol and myoinositol of diabetic and nondiabetic patients with normal kidney function and of diabetic and non-diabetic patients with impaired kidney function were measured by gas-liquid chromatography. The CSF sorbitol level correlated with the plasma glucose level (p≦0.05) in diabetic patients with normal kidney function, having received insulin for less than 12 months. The correlation between CSF sorbitol and plasma glucose levels in patients not dependent on insulin was not significant. Sorbitol was not detected in the plasma. The highest sorbitol levels in CSF were seen in insulin-dependent diabetic patients with impaired kidney function. No rise was seen in non-diabetic uremia. 1,5-anhydroglucitol, normally present in plasma, was absent from CSF and plasma in diabetic patients receiving insulin. In non-diabetic uremic patients 1,5-anhydroglucitol levels in CSF and plasma were lower than in healthy subjects, but there was no correlation with plasma glucose levels. The myoinositol level was higher in CSF than in the plasma of both non-diabetic and diabetic patients with normal kidney function. Both plasma and CSF levels were significantly (p<0.001) elevated in diabetic as well as in non-diabetic uremic patients, the plasma myoinositol increasing relatively more than the CSF levels. The elevation of plasma myoinositol correlated with the elevation of plasma creatinine and thus also with the impairment of kidney function. Plasma and CSF myoinositol levels were not influenced by the plasma glucose level.

Key words

1,5-anhydroglucitol myoinositol sorbitol diabetes uremia 


  1. 1.
    Gabbay, K.F.: The sorbitol pathway and the complications of diabetes. New Engl. J. Med.288, 831–836 (1973)Google Scholar
  2. 2.
    Ward, J.D., Baker, R.W.R., Davies, B.H.: Effect of blood sugar control on the accumulation of sorbitol and fructose in nervous tissue. Diabetes21, 1973–1978 (1972)Google Scholar
  3. 3.
    Gabbay, K.H.: Factors affecting the sorbitol pathway in diabetic nerve. Diabetes18 (Suppl. 1), 336–337 (1969)Google Scholar
  4. 4.
    Schofield, P.J., Hutton, J.C., Williams, J.F.: Polyol synthesis by monkey kidney epithelial cells in culture. IRCS (Research on: biochemistry; biophysics, membrane and cell biology; kidneys and urinary system; metabolism and nutrition)2, 1465 (1974)Google Scholar
  5. 5.
    de Jesus, P.V., Clements, R.S., Winegrad, A.I.: Hypermyoinositolemic polyneuropathy in rats. J. neurol. Sci.21, 237–249 (1974)Google Scholar
  6. 6.
    Clements, R.S.: Myoinositol metabolism in diabetes mellitus. Diabetes23 (Suppl. 1, Abstract), 348 (1974)Google Scholar
  7. 7.
    Clements, R.S., de Jesus, P.V., Winegrad, A.I.: Raised plasma myoinositol levels in uremia and experimental neuropathy. Lancet1973 I, 1137–1141Google Scholar
  8. 8.
    Pitkänen, E.: Occurence of 1,5-anhydroglucitol in human cerebrospinal fluid. Clin. chim. Acta48, 159–166 (1973)Google Scholar
  9. 9.
    Pitkänen, E., Servo, C.: Cerebrospinal fluid polyols in patients with diabetes mellitus. Clin. chim. Acta44, 437–442 (1973)Google Scholar
  10. 10.
    Daughaday, W.H., Larner, J.: Renal excretion of inositol in normal and diabetic human beings. J. clin. Invest.33, 326–332 (1954)Google Scholar
  11. 11.
    Malaisse, W.J., Sener, A., Mahy, M.: The stimulus-secretion coupling of glucose induced insulin release. Sorbitol metabolism in isolated islets. Europ. J. Biochem.47, 365–370 (1974)Google Scholar
  12. 12.
    Pitkänen, E.: The serum polyol pattern and the urinary polyol excretion in diabetic and uremic patients. Clin. chim. Acta38, 221–230 (1972)Google Scholar
  13. 13.
    Servo, C.: The sorbitol level in CSF in diabetic patients. Acta Endocrinol. (Kbh.)77, (Suppl. 190, Abstract), 80 (1974)Google Scholar

Copyright information

© Springer-Verlag 1975

Authors and Affiliations

  • C. Servo
    • 1
  • E. Pitkänen
    • 1
  1. 1.Fourth Dept. of MedicineUniv. of HelsinkiHelsinkiFinland

Personalised recommendations